These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

934 related items for PubMed ID: 22946753

  • 21. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
    Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.
    Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
    [Abstract] [Full Text] [Related]

  • 22. BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation.
    Young K, Minchom A, Larkin J.
    Future Oncol; 2012 May; 8(5):499-507. PubMed ID: 22646765
    [Abstract] [Full Text] [Related]

  • 23. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.
    Kim G, McKee AE, Ning YM, Hazarika M, Theoret M, Johnson JR, Xu QC, Tang S, Sridhara R, Jiang X, He K, Roscoe D, McGuinn WD, Helms WS, Russell AM, Miksinski SP, Zirkelbach JF, Earp J, Liu Q, Ibrahim A, Justice R, Pazdur R.
    Clin Cancer Res; 2014 Oct 01; 20(19):4994-5000. PubMed ID: 25096067
    [Abstract] [Full Text] [Related]

  • 24. The role of BRAF V600 mutation in melanoma.
    Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N.
    J Transl Med; 2012 Jul 09; 10():85. PubMed ID: 22554099
    [Abstract] [Full Text] [Related]

  • 25. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
    Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D, BRIM8 Investigators.
    Lancet Oncol; 2018 Apr 09; 19(4):510-520. PubMed ID: 29477665
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
    Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Yan Y, Wongchenko M, Chang I, Hsu JJ, Koralek DO, Rooney I, Ribas A, Larkin J.
    Lancet Oncol; 2016 Sep 09; 17(9):1248-60. PubMed ID: 27480103
    [Abstract] [Full Text] [Related]

  • 28. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A, Larkin J, Ribas A, Dréno B, Flaherty KT, Ascierto PA, Lewis KD, McKenna E, Zhu Q, Mun Y, McArthur GA.
    JAMA Oncol; 2018 Oct 01; 4(10):1382-1388. PubMed ID: 30073321
    [Abstract] [Full Text] [Related]

  • 29. The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
    da Rocha Dias S, Salmonson T, van Zwieten-Boot B, Jonsson B, Marchetti S, Schellens JH, Giuliani R, Pignatti F.
    Eur J Cancer; 2013 May 01; 49(7):1654-61. PubMed ID: 23481513
    [Abstract] [Full Text] [Related]

  • 30. Cobimetinib.
    Signorelli J, Shah Gandhi A.
    Ann Pharmacother; 2017 Feb 01; 51(2):146-153. PubMed ID: 27701080
    [Abstract] [Full Text] [Related]

  • 31. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective.
    Fleeman N, Bagust A, Beale S, Boland A, Dickson R, Dwan K, Richardson M, Dundar Y, Davis H, Banks L.
    Pharmacoeconomics; 2015 Sep 01; 33(9):893-904. PubMed ID: 25906420
    [Abstract] [Full Text] [Related]

  • 32. Vemurafenib in melanoma.
    Shaw HM, Nathan PD.
    Expert Rev Anticancer Ther; 2013 May 01; 13(5):513-22. PubMed ID: 23617343
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C, How-Kit A, Battistella M, Sadoux A, Podgorniak MP, Sidina I, Pages C, Roux J, Porcher R, Tost J, Mourah S.
    Melanoma Res; 2014 Aug 01; 24(4):415-8. PubMed ID: 24933605
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.